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Islet transplantation is one of the most promising therapies for type 1 diabetes (T1D). A major issue in islet 
transplantation is the loss of graft function at late phase. Several studies suggested the involvement of islet- 
specific T-cells in such islet graft dysfunction. In this study, we investigated the breadth and type of glu-
tamic acid decarboxylase 65 (GAD65)-specific T-cells in T1D patients after allogeneic islet transplantation. 
Peripheral blood mononuclear cells (PBMCs) were obtained from islet-transplanted T1D patients during insulin- 
independent period and cultured for 7 days with pools of GAD65 overlapping peptides in the presence of IL-2. 
Cytokine secretion profiles of peptide-reactive T-cells were analyzed after a short-term restimulation with the 
same peptides by a multiplex bead-based cytokine assay and by an intracytoplasmic cytokine detection assay. 
Robust GAD65-specific CD4+ and CD8+ T-cell responses were detected in patients who eventually developed 
chronic graft dysfunction. Multiple GAD65 peptides were found to induce specific T-cell responses in these 
patients, indicating that the repertoire of GAD65-specific T-cells was broad. Furthermore, GAD65-specific 
CD4+ T-cells were composed of heterogeneous populations, which differentially expressed cytokines including 
IFN-g and type 2 cytokines, but not IL-10. In contrast, patients who showed only marginal GAD65-specific 
T-cell responses maintained substantially longer graft survival and insulin independence. In conclusion, our 
study suggests that the emergence of islet-specific T-cells precedes the development of chronic graft dysfunc-
tion in islet-transplanted patients. Thus, our observations support the hypothesis that these islet-specific T-cells 
contribute to the development of chronic islet graft dysfunction.
Key words: Islet transplantation; Type 1 diabetes (T1D); Graft dysfunction; Glutamic acid decarboxylase 65 
(GAD65); T-cells
directly associated with the pathogenesis of T1D (35,38,42). 
Consistently, T1D patients have been found to display 
GAD65-specific CD4+ and CD8+ T-cells in blood (7).
Islet transplantation is one of the most promising ther-
apies for T1D. Approximately 70% of patients achieve insu-
lin independence after islet transplantation. However, only 
approximately 50% of those patients maintain insulin inde-
pendence for more than 2 years (1) and only 10% for more 
than 5 years (27). Therefore, loss of islet graft function at 
late phase is a current major issue in islet transplantation. In 
INTRODUCTION
Type 1 diabetes (T1D) is caused by autoimmunity-
 based destruction of insulin-producing islet b-cells (3, 
10,24). While a majority of T1D patients display serum anti-
bodies specific for islet antigens, including glutamic acid 
decarboxylase 65 (GAD65), insulinoma antigen-2 (IA-2), 
and insulin, islet-specific T-cells appear to play a major role 
in the development of T1D (25,39). GAD65 is one of the 
best characterized among islet antigens (4,17,23,36), and 
mouse studies demonstrate that GAD65-specific T-cells are 
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acute islet graft rejection, T-cells recognizing alloantigens 
(i.e., alloreactive T-cells) expressed by transplanted islets 
appear to be instrumental. In contrast, islet-specific T-cells 
rather than alloreactive T-cells have been suggested to play 
a major role in chronic islet graft dysfunction. Several stud-
ies showed that patients who lost islet functions after trans-
plantation display islet antigen-specific T-cells in blood 
(12,22,26). These conclusions were drawn either by analyz-
ing T-cell proliferation in response to stimulation with islet-
specific proteins in vitro or by staining peripheral blood 
mononuclear cells (PBMCs) with islet-specific human 
leukocyte antigen (HLA) class I tetramers. However, the 
breadth and the type of islet-specific T-cells emerging after 
islet transplantation remain largely unknown.
In this study, we analyzed GAD65-specific T-cell 
responses in T1D patients who received islet transplan-
tation. To determine the breadth and type of GAD65-
specific T-cells, we took advantage of overlapping 
peptide library, which permits simultaneous detection of 
both CD4+ and CD8+ antigen-specific T-cell responses 
in cultures. We show that a broad repertoire of GAD65-
specific T-cells was present in patients who eventually 
developed graft dysfunction. GAD65-specific T-cells 
in these patients contained interferon (IFN)-g-secreting 
type 1 helper T-cells (Th1 cells) as well as interleukin 
(IL)-13-producing type 2 helper T-cells (Th2 cells) and 
IFN-g-producing CD8+ T-cells. In contrast, GAD65-
specific T-cells were virtually absent in patients who 
have maintained long-term graft survival.
MATERIALS AND METHODS
Patients
Six T1D patients who received allogeneic islet trans-
plantation participated in this study. Islet isolation and 
transplantation were performed as previously described 
(19,20). Three patients received daclizumab, and the other 
three received anakinra and etanercept as anti-inflammatory 
therapy and thymoglobulin for the induction therapy of 
immunosuppression (20). All of six patients received 
tacrolimus with mycophenolate mofetil (MMF) for the 
maintenance therapy of immunosuppression (20). All the 
patients participating in this study signed informed con-
sent forms from an institutional review board-approved 
protocol (project No. 008-095). In this study, we defined 
“chronic graft dysfunction” as the condition where insulin 
injection becomes required after an insulin-independent 
period due to the deterioration of endogenous insulin 
secretion.
Monitoring Islet Graft Function
A secretory unit of islet transplant objects (SUITO) index, 
which reflects the functional engrafted islet mass (18,21), 
was used to assess the islet graft function. The formula of 
the SUITO index is as follows: fasting C-peptide (ng/ml) / 
[fasting blood glucose (mg/dl) - 63] ´  1,500. A SUITO index 
of 100 reflects 100% pancreatic b-cell function in a healthy 
person. A SUITO index of more than 26.0 was shown to be 
associated with insulin independence (18,21).
Blood Samples
Peripheral blood samples were obtained from the islet 
transplanted recipients at various time points. PBMCs 
were isolated by density gradient centrifugation, using 
Ficoll-Paque PLUS (GE-Healthcare Bio-Sciences, 
Piscataway, NJ) from sodium-heparinized blood within 
24 h after sampling. Serum was stored at -80°C.
Autoantibody Measurement
Anti-GAD65 antibody (GAD65-Ab) in serum was 
measured by a combined radiobinding assay at the 
Barbara Davis Center for Childhood Diabetes, Univer sity 
of Colorado, Denver, as previously described (37,40). 
Briefly, labeled recombinant GAD65 (3H-GAD65) 
was produced by in vitro transcription/translation. The 
radioassay was performed on a 96-well filtration plate 
(Fisher Scientific, Loughborough, UK), and radioactiv-
ity was counted on a TopCount 96-well plate b-counter 
(PerkinElmer Life Sciences, Wilmington, DE). Serum 
antibody titers were indicated as an index of radio-
activity. The upper limits of normal, nondiabetic sub-
jects’ sera were established as the 99th percentile value 
in healthy controls.
Overlapping Peptide Libraries
A 15-mer overlapping peptide library was designed 
to cover the entire 585 amino acids sequence of 
GAD65 with four amino acids lagging (144 peptides, 
BioSynthesis, TX) (Table 1). Peptides were dissolved at 
10 mM with 50% acetonitrile (Sigma-Aldrich Co., St. 
Louis, MO) and pooled into clusters containing 10–11 
peptides, which resulted in the generation of 14 peptide 
clusters (C1–C14) (Table 2). Peptide clusters were kept 
frozen at -80°C.
Cell Culture
PBMCs were resuspended at a concentration of 
2.5 ´  106 cells/ml in complete medium [CM; RPMI 1640 
medium (GIBCO, Carlsbad, CA) supplemented with 1% 
l- glutamine (Sigma), 1 % penicillin/streptomycin (Sigma), 
50 mM 2-b-mercaptoethanol (Sigma), 1% sodium pyruvate 
(Sigma), 1% nonessential amino acid (Sigma), and 10% 
heat-inactivated human AB serum (Gemini Bio-Products, 
Sacramento, CA)]. The cell viability was examined with 
0.4% trypan blue solution (Sigma) and was always >95%. 
Cells (5 ´  105 cells per well) were cultured in a 96-well 
deep well plate in the presence of GAD65 peptide clus-
ters (10 mM each peptide). Equal amount of peptide 
diluent was used as a negative control. Staphylococcal 
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enterotoxin B (SEB; 0.1 mg/ml) was used as a positive 
control. To expand the antigen-specific T-cells, 100 U/ml 
recombinant human IL-2 [TECIN (Teceleukin); Roche] 
was added to the culture at day 2 of culture. Cells were 
harvested on day 7 and split into two cultures for intra-
cytoplasmic cytokine detection assay and cytokine secre-
tion assay.
Intracytoplasmic Cytokine Detection
Cultured PBMCs were resuspended with CM at a con-
centration of 1.0 ´  106 cells/ml and restimulated with the 
same GAD65 peptide clusters (10 mM per peptide) for 
6 h. Brefeldin A (Golgi PlugTM; BD Biosciences, San Jose, 
CA) was added for the last 4 h of culture. After surface 
staining, cells were fixed, permeabilized, and then stained 
for intracytoplasmic cytokines. CD8 peridinin chloro-
phyll protein complex (PerCP; SK1) was obtained from 
BD Pharmingen. CD3 allophycocyanin (APC)-Alexa 
Fluor 750 (S4.1) and CD4 phycoerythrin-cyanine 7 
(PE-Cy7; S3.5) were obtained from Invitrogen. IL-13 
APC (JES10-5A2) and IFN-g Pacific Blue (4S.B3) were 
obtained from Biolegend. Stained cells were analyzed 
with FACSCantoIITM flow cytometer (BD Biosciences), 
and the data were analyzed by the software FLOWJO 
(Tree Star, Inc., Ashland, OR).
Cytokine Secretion Assay
Cultured PBMCs were resuspended with CM con-
taining carboxyfluorescein succinimidyl ester (CFSE) 
at a concentration of 1.0 ´  106 cells/ml and restimulated 
with the same GAD65 peptide clusters (10 mM per pep-
tide) for 24 h. Secreted cytokine levels [IL-5, IL-10, 
IL-13, IL-17A, IL-21, tumor necrosis factor (TNF)-a, 
and IFN-g ] were measured by a multiplex bead-based 
cytokine assay (BIO-RAD). Data were analyzed using 
the software GraphPad PRISM. In some figures, for the 
visualization of the secreted cytokine levels, the data 
were transformed into a heat-map format indicating the 
fold increase from the background.
RESULTS
Clinical Outcomes of Islet Transplantation
Patients and clinical characteristics were shown in 
Table 3. Serum C-peptide was undetectable in Pts. #1–5 
before transplantation, indicating that pancreatic b-cell 
function was totally abolished. Five patients (Pts. #1–5) 
achieved insulin independence, whereas one patient 
(Pt. #6) experienced immediate islet graft loss (Table 3). 
As of June 2011, Pts. #1, #2, and #3 have been main-
taining a high SUITO index and insulin independence 
for 155, 78, and 114 weeks posttransplant, respectively 
(Table 3, Fig. 1). In contrast, Pts. #4 and #5 did not main-
tain their SUITO index at greater than 26 and restarted 
insulin injection at 37 and 46 weeks after the second islet 
transplantation, respectively. In Pt. #6, while the SUITO 
index reached 35.0 at 1 week posttransplantation, the 
index dropped to 6.3 at week 2. This patient received 
~10,000 IEQ/kg islets, and thus, the rapid graft failure 
was unlikely due to graft insufficiency.
Serum GAD65-Ab Titers in Islet Transplantation
To analyze whether chronic graft dysfunction is 
associated with the increase of GAD65-specific anti-
body titers, we measured serum GAD65-Ab titers 
before and after islet transplantation (Table 3, Fig. 2). 
Only Pt. #4, who developed chronic graft dysfunction, 
displayed GAD65-Ab before transplantation (Table 3) 
Table 1. Layout of GAD65 Overlapping Peptide Library

























Table 2. Layout of GAD65 Peptide Clusters
Cluster # Peptide # Cluster # Peptide #
C1 1–10 C8 71–80
C2 11–20 C9 81–90
C3 21–30 C10 91–100
C4 31–40 C11 101–111
C5 41–50 C12 112–122
C6 51–60 C13 123–133
C7 61–70 C14 134–144
C, peptide cluster.
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and maintained high titers posttransplantation (Fig. 2B). 
Pt. #6, who experienced immediate graft function loss, 
rapidly developed GAD65-Ab after transplantation. 
Pt. #5, who restarted insulin injection at 63 weeks after 
transplantation due to chronic graft dysfunction, showed 
GAD65-Ab transiently at weeks 77–90 (Fig. 2B). Pts. #2 
and #3, who maintained long-term graft survival, 
remained negative for serum GAD65-Ab at all the time 
points (Fig. 2A).
Thus, three of the three patients who developed acute 
or chronic graft dysfunction showed serum GAD65-Ab at 
multiple time points posttransplantation.
GAD65-Specific T-Cells in Islet Transplantation
To determine the type and breadth of GAD65-
specific T-cells after islet transplantation, we cultured 
PBMCs obtained from patients with pools of GAD65 
overlapping peptides (14 peptide clusters; C1–C14). 
To expand the peptide-reactive T-cells, IL-2 was added 
to cultures at day 2 and day 5. Cultured cells were har-
vested at day 7 and restimulated with the same GAD65 
peptides for 24 h to measure cytokine production by 
the expanded specific T-cells (Fig. 3). PBMCs were 
obtained from Pts. #1–5 when islet graft functions 
were still maintained (Fig. 1). In three patients, Pts. #1, 
#2, and #3, who maintained long-term graft survival, 
cytokine secretion in response to GAD65 peptides was 
very limited, and only a few peptide clusters induced 
cytokine secretion (Fig. 3A, B). This observation sug-
gests that the repertoire of GAD65-specific T-cells in 
these patients was limited, and the frequency of these 
cells in peripheral blood was low. In contrast, in Pts. #4 
and #5, who developed chronic graft dysfunction at 
late phase, multiple cytokines were robustly secreted 
in response to multiple GAD65 peptide clusters, sug-
gesting the presence of a broad repertoire of GAD65-
specific T-cells. Expanded GAD65-specific T-cells 
produced variable types of cytokines including type 1 
(IFN-g) and type 2 cytokines (IL-5 and IL-13) 
(Fig. 3C, D). The difference in GAD65-specific T-cell 
responses between long-term graft survival group and 
graft dysfunction group was not due to the differ-
ence in the overall T-cell reactivity, as CD4+ T-cells 
stimulated with a superantigen SEB as a positive con-
trol secreted comparable levels of cytokines includ-
ing IL-13 and IFN-g between the two groups (Fig. 4). 
Of note, expanded GAD65-specific T-cells did not 
produce IL-10 either in the long-term graft survival 
group (Figs. 3B, 5A) or in the chronic graft dysfunc-
tion group (Figs. 3D, 5B). This was in contrast to the 
secretion of IL-10 by GAD65-specific T-cells in non-
diabetic healthy individuals (Fig. 5C).
Table 3. Clinical Characteristics of the Patients Who Received Islet Transplantation
Long-Term Graft Survival Graft Dysfunction
Pt. #1 Pt. #2 Pt. #3 Pt. #4 Pt. #5 Pt. #6
Pretransplantation
Age, gender 55y, F 38y, F 53y, F 55y, F 51y, F 35, F
Disease duration (years) 43 33 44 16 38 25
BMI (kg/m2) 23.4 20.7 27.9 29.9 26.6 21.2
HLA-DR 4, 8 3, 4 4, 17 3, 13 4, 13 4, 17
GAD65 antibody – – – + – –
C-peptide (ng/ml) 0.0 0.0 0.0 0.0 0.0 0.3
SUITO index 0.0 0.0 0.0 0.0 0.0 5.6
HbA1c (%) 8.3 8.4 9.4 8.3 7.4 6.2
Posttransplantation
Transplanted islets (IEQ/kg) 28,114 18,275 12,010 12,096 13,496 9,367
Immunosuppression
Induction therapy Dac/Eta ATG/Ana/Eta ATG/Ana/Eta Dac/Eta Dac/Eta ATG/Ana/Eta
Maintenance therapy Tac/MMF Tac/MMF Tac/MMF Tac/MMF Tac/MMF Tac/MMF
C-peptide (ng/ml)a 2.4 1.3 1.3 3.2 1.2 0.1
SUITO indexa 64.3 28.3 30.5 77.4 20.2 4.3
HbA1c (%)a 5.4 5.5 6.2 5.9 6.6 5.9
Insulin independence (period) 155 weeks+ 78 weeks+ 114 weeks+ 37 weeks 46 weeks 0 week
Still insulin independent Yes Yes Yes No No No
Dac, daclizumab; Eta, etanercept; ATG, thymoglobulin; Ana, anakinra; Tac, tacrolimus; MMF, mycophenolate mofetil. BMI, body mass index; GAD65, 
glutamic acid decarboxylase 65; hbA1c, glycated hemoglobin; HLA, human leukocyte antigen; SUITO, secretory unit of islet transplant objects.
aEach value was evaluated when the first blood samples were drawn after islet transplantation.
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To analyze the cytokine expression by GAD65-specific 
T-cells at a single-cell level, intracytoplasmic cytokine 
expression by the expanded GAD65-specific T-cells was 
analyzed. As GAD65 peptide cluster #4 (C4) induced the 
highest magnitude of cytokine production in both Pts. #4 and 
#5 (Fig. 3C, D), we focused our analysis on the cells specific 
for this set of peptides. As shown in Figure 3E, GAD65-
specific CD4+ T-cells in Pt. #4 dominantly expressed IFN-g 
(thus are Th1 cells), and some expressed both IFN-g and 
IL-13. GAD65-specific CD4+ T-cells in Pt. #5 were com-
posed of IFN-g-expressing Th1 cells, IL-13-expressing Th2 
cells, and cells coexpressing IFN-g and IL-13. Furthermore, 
both patients displayed IFN-g-expressing GAD65-specific 
CD8+ T-cells (Fig. 3E). These observations show that 
GAD65-specific T-cells emerging after islet transplantation 
include both CD4+ and CD8+ T-cells. GAD65-specific CD4+ 
Figure 1. Clinical course after islet transplantation. Pts. #1, #2, and #3 maintained higher secretory unit of islet transplant objects 
(SUITO) index and insulin independence, while Pts. #4, #5, and #6 developed graft dysfunction. Glutamic acid decarboxylase 65 
(GAD65)-specific T-cell responses were analyzed in Pts. #1–5 when islet graft functions were maintained. Dotted lines indicate the 
reference SUITO index level (score 26.0), which reflects the borderline of insulin injection requirement. I.I., insulin independence.
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T-cells were composed of heterogeneous cell populations 
expressing different sets of cytokines.
We were able to follow GAD65-specific T-cell 
responses at multiple points after islet transplantation in 
two patients, Pts. #1 and #5 (Fig. 5). Pt. #1, who has been 
maintaining graft survival for more than 155 weeks, did 
not display strong GAD65-specific T-cell responses even 
at 143 weeks posttransplantation. In contrast, in Pt. #5 
who restarted insulin injection 63 weeks after the first 
transplantation, IFN-g-secreting T-cells in response to 
GAD65 C4 peptides were detected as early as at 15 weeks. 
At later time points, cytokine secretion in response to 
GAD65 C4 increased, and secretion of cytokines other 
than IFN-g, such as IL-5 and IL-13, became detectable 
(Fig. 6). Thus, in Pt. #5, the magnitude of GAD65-
specific T-cell response increased according to the prog-
ress of graft dysfunction, and such T-cells expressed more 
variable types of cytokines at late phase.
A Patient With Immediate Loss of Islet Function  
After Transplantation Displayed Persistent  
GAD65-Specific CD8+ T-Cell Responses  
Even Under Thymoglobulin Administration
We analyzed GAD65-specific T-cell responses in Pt. #6 
whose islet function was immediately lost after trans-
plantation. At pretransplantation, a broad repertoire of 
GAD65-speficic T-cells was detectable, and multiple 
GAD peptide clusters, including C2, C3, C4, C5, C6, C10, 
Figure 2. The kinetics of serum GAD65-Ab titers. Serum GAD65-Ab titers in patients who maintained long-term graft survival (A) 
and patients who developed graft dysfunction (B). Dotted lines indicate the cutoff value of the 99th percentile of normal controls. I.I., 
insulin independence.
FACING PAGE
Figure 3. GAD65-specific T-cell responses in type 1 diabetes (T1D) patients after islet transplantation. T-cell responses were analyzed 
when islet functions were preserved. Peripheral blood mononuclear cells (PBMCs) were stimulated with GAD65 peptide clusters 
(C1–C14) in duplicate and cultured for 7 days in the presence of interleukin (IL)-2. Seven cytokines secreted during 24 h restimulation 
were measured by a multiplex bead-based cytokine assay. (A, C) IL-13 and interferon (IFN)-g secretion in patients with long-term 
graft survival (A) and with chronic graft dysfunction (C). Data were expressed as mean ± SD. (B, D) Cytokine data were transformed 
into a heat-map format indicating the fold increase from the background. Blue indicates the strongest cytokine secretion, whereas yel-
low indicates the background. (E) Intracellular cytokine expression by T-cells in response to GAD65 C4 in patients who eventually 
developed chronic graft rejection. The expression of intracytoplasmic cytokines was analyzed by flow cytometry 6 h after restimula-
tion with same peptide clusters.
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and C14, induced cytokine secretion by the expanded 
T-cells (Fig. 7A, left; B, left). The type of cytokines 
secreted by the expanded GAD65-specific T-cells was 
variable and included IL-10, IL-13, IL-17A, and IFN-g 
(Fig. 7A, left; B, left). Intracytoplasmic cytokine detec-
tion assay showed that GAD65-specific CD4+ T-cells 
included IFN-g-producing Th1 cells, IL-13-producing 
Th2 cells, and IL-13/IFN-g coexpressing cells. Moreover, 
IFN-g-producing CD8+ T-cells were also detected spe-
cific for multiple GAD65 peptides, including C3, C6, and 
C14 (Fig. 7B, left).
To analyze GAD65-specific T-cell responses after islet 
transplantation, we obtained blood sample at 4 weeks 
posttransplantation. As thymoglobulin was admi-
nistered for induction of immunosuppression in this 
patient, the frequency of T-cells in blood was very low 
at the sampling. Therefore, we focused our assay on 
the five peptide clusters (C3, C4, C5, C6, and C14), 
which induced cytokine responses before transplanta-
tion (Fig. 7B). At 4 weeks posttransplantation, IFN-g 
was secreted in response to C6 (Fig. 7A, right; B, right). 
Intracytoplasmic cytokine detection assay revealed that 
IFN-g was expressed by mostly GAD65-specific CD8+ 
T-cells (Fig. 7B, right). Thus, GAD65-specific CD8+ 
T-cells were present in this patient even when the total 
blood T-cell number was low.
DISCUSSION
In this study, we analyzed the breadth and type of 
GAD65-specific T-cell responses in T1D patients after 
allogeneic islet transplantation. GAD65-specific T-cells 
were barely detected in three of three long-term graft 
survivors, whereas GAD65-specific CD8+ T-cells were 
detected in three of three patients with acute or chronic 
graft dysfunction. A longitudinal analysis in a patient 
with chronic graft dysfunction showed an increase of 
the magnitude and the type of GAD65-specific T-cells 
during the clinical course. These results suggest that 
the emergence of proinflammatory T-cells specific 
for islet antigens is associated with chronic graft dys-
function in islet transplantation in T1D. Consistently, 
involvement of autoreactive immunity in chronic 
graft failure has also been demonstrated in mouse 
transplantation models of heart (29) and skin (32), 
as well as in human organ transplantations, including 
liver transplantation for autoimmune liver diseases 
(6,8,15,34) and whole pancreas transplantation for 
T1D (13,16,33). Importantly, our study showed that 
GAD65-specific T-cell responses became detectable 
when patients were still maintaining graft function and 
insulin independence and preceded the occurrence of 
chronic graft dysfunction. Therefore, analysis of islet 
antigen-specific T-cell repertoires might be useful to 
predict impending chronic graft dysfunction after islet 
transplantation.
Our study also suggests that GAD65-specific CD4+ 
T-cells emerging in chronic graft dysfunction patients 
are heterogeneous and composed of populations that dif-
ferentially express IFN-g and type 2 cytokines, includ-
ing IL-5 and IL-13. Given that IFN-g is involved in the 
development of T1D (9,25), IFN-g likely plays a patho-
genic role also in chronic graft dysfunction. In contrast, 
the role of type 2 cytokines in chronic graft dysfunction 
is unclear. A previous study shows that insulin-specific 
T-cell clones established from pancreatic lymph nodes of 
T1D patients preferentially secreted IL-13, but not IFN-g 
(14). Therefore, type 2 cytokines might also contribute 
to the destruction of transplanted islet grafts. On the 
contrary, it is possible that type 2 cytokines play an anti- 
inflammatory role. For example, a systemic administra-
tion of recombinant IL-13 prevents the onset of diabetes 
in non-obese diabetic (NOD) mice (41). Furthermore, 
generation of IL-5-producing GAD65-specific CD4+ 
T-cells was shown to protect NOD mice from diabetes 
development (30).
Notably, IL-10-producing GAD65-specific CD4+ 
T-cells were not detected in any patients posttransplan-
tation. This was not due to technical limitation in our 
Figure 4. T-cell responses stimulated by staphylococcal entero-
toxin B (SEB) in T1D patients after islet transplantation. PBMCs 
were stimulated with 0.1 mg/ml of SEB in duplicate and cultured 
for 7 days in the presence of IL-2. Seven cyto kines secreted dur-
ing 24 h restimulation were measured by a multiplex bead-based 
cytokine assay. Each value of IL-13 (A) and IFN-g (B) from 
duplicates in three long-term graft survival patients (open circle) 
and two graft dysfunction patients (closed circle) were plotted. 
NS, no significant difference assessed by Student’s t test.
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assays, as IL-10-producing GAD65-specific T-cells were 
detected in samples from healthy individuals as well as 
from a T1D patient (Pt. #6 at pretransplantation). While 
such IL-10-producing T-cells might act as regulators of 
proinflammatory effector T-cells (2,31), our data suggest 
that chronic graft dysfunction is associated more with the 
development of proinflammatory islet antigen-specific 
T-cells rather than the failure of development of IL-10-
producing regulatory T-cells.
When compared to GAD65-specific T-cell assay, the 
correlation between serum GAD65-Ab titers and insulin 
independency was not so clear-cut in our study, at least 
partly due to transient GAD65-Ab appearance in sera in 
several patients. Transient development of autoantibodies 
Figure 5. GAD65-specific IL-10 responses in T1D patients who maintained long-term graft sur-
vival (A), T1D patients who eventually developed chronic graft dysfunction (B), and nondiabetic 
healthy individuals (C). PBMCs were stimulated with GAD65 peptide clusters (C1–C14) and cul-
tured for 7 days in the presence of IL-2. IL-10 secreted during 24 h restimulation was measured.
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specific for islet antigens including GAD65 is observed 
even in healthy subjects without association with the 
risk of onset of T1D (11), and the mechanism of their 
development is unknown. Thus, measurement of serum 
GAD65-Ab alone may not be sufficient to predict the 
clinical outcome. Measurement of multiple islet auto-
antibodies at multiple time points posttransplantation 
might provide a better biomarker in this context, as shown 
previously (5,12,28).
A limitation of this study was the lack of a pre-
transplant analysis except in one patient. Therefore, 
whether GAD65-specific T-cells detected posttrans-
plantation are derived from preexisting repertoire or 
newly developed after transplantation is unknown. A 
systematic comparison regarding islet-antigen specific 
T-cell repertoires between before and after transplan-
tation should reveal their developmental mechanism 
after transplantation.
In conclusion, our study supports the hypothesis that 
development of islet antigen-specific T-cell immunity 
is associated with chronic islet graft dysfunction after 
allogeneic islet transplantation. A larger-scale study 
should reveal the efficiency of analysis of islet antigen-
specific T-cells in the prediction of clinical outcomes. 
Importantly, such study might provide insights in the 
development of novel approach to prevent chronic islet 
graft dysfunction. Successful immunosuppressive ther-
apy against these antigen-specific T-cells may prolong 
islet function and survival in allotransplantation for 
T1D recipients.
Figure 6. Longitudinal analysis of GAD65-specific T-cell responses. GAD65-specific T-cell responses were analyzed at different 
time points after transplantation by multiplex bead-based cytokine assays. Pt. #1 maintained long-term graft survival, whereas Pt. #5 
developed chronic graft dysfunction at 46 weeks after the second transplantation. Fold increase of cytokine levels from the background 
is shown in a heat-map format. Each patient received islet transplantation twice shown by red triangles. w, weeks after the first islet 
transplantation.
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Figure 7. GAD65-specific T-cell responses in a patient whose islet function was immediately lost after transplantation. T-cell responses 
were analyzed before and 4 weeks after islet transplantation. Carboxyfluorescein succinimidyl ester (CFSE)-labeled PBMCs were 
stimulated with GAD65 peptide clusters (C1–C14) in duplicate and cultured for 7 days in the presence of IL-2. Seven cytokines 
secreted during 24 h restimulation were measured. IL-13 and IFN-g responses before and 4 weeks after islet transplantation are shown 
in (A). Data were expressed as mean ± SD. Fold increase of cytokine levels from the background is shown in a heat-map format (B, top). 
The expression of intracytoplasmic cytokines was analyzed by flow cytometry 6 h after restimulation with same peptide clusters (B, bottom). 
Gated to CFSE-negative (thus proliferating) CD4+ or CD8+ T-cell populations.
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